Medication Ordering – Opioid Naming with respect to Release Profile

Purpose

To provide clinicians with a guide to opioid naming with respect to release profile in Expanse.

Audience

All clinicians that prescribe, verify or administer opioids

Version Control

| Version	Date	Author	Changes Made
1.0	16-Nov-2025	Louisa Conlon, Expanse Pharmacy	Initial draft

Medication Ordering
– Opioid Naming with respect to Release Profile

This guide outlines the rationale for opioid naming with respect to release profile in Expanse
- Part 1: Immediate Release Formulations
- Part 2: Modified Release Formulations

Part 1: Immediate Release Formulations

Immediate release formulation names do NOT contain the words 'immediate release'. This is as per SNOMED/dm+d international naming convention.

Immediate release formulation products are built at VMPP dm+d level (manufacturer-independent) as per national recommendations/best practice as they do not have bioavailability differences, release profile variations nor specific device directions.

Part 2: Modified Release Formulations

Modified release formulation names contain the acronym 'MR'. This is as per SNOMED/dm+d international naming convention with an abbreviation due to character length restrictions in Expanse name fields.

Modified release formulation products are built at AMPP dm+d level (manufacturer-dependent) as per national recommendations/best practice as they have release profile variations or specific device directions.